Xencor (NASDAQ:XNCR) Stock Passes Above Fifty Day Moving Average - What's Next?

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $8.55 and traded as high as $9.48. Xencor shares last traded at $9.28, with a volume of 772,711 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on XNCR shares. Wedbush reiterated an "outperform" rating and issued a $31.00 price objective on shares of Xencor in a research report on Wednesday, April 30th. Barclays decreased their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. Finally, William Blair initiated coverage on Xencor in a report on Monday, April 21st. They set an "outperform" rating for the company. Two analysts have rated the stock with a sell rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $28.00.

Xencor Trading Up 0.2%

The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.89 and a current ratio of 5.89. The stock has a fifty day moving average of $8.50 and a 200-day moving average of $12.72. The company has a market cap of $629.85 million, a PE ratio of -2.89 and a beta of 0.85.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). The firm had revenue of $32.73 million for the quarter, compared to the consensus estimate of $23.44 million. Xencor had a negative net margin of 181.17% and a negative return on equity of 31.94%. The company's revenue for the quarter was up 104.6% on a year-over-year basis. During the same period last year, the firm earned ($1.11) earnings per share. Sell-side analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ellen Feigal sold 2,993 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the transaction, the director directly owned 19,183 shares of the company's stock, valued at $176,867.26. This represents a 13.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Nancy Valente sold 4,616 shares of the company's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.03, for a total value of $50,914.48. Following the transaction, the executive vice president directly owned 49,169 shares in the company, valued at $542,334.07. This represents a 8.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,810 shares of company stock valued at $154,123. 5.23% of the stock is currently owned by corporate insiders.

Institutional Trading of Xencor

Hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its holdings in shares of Xencor by 0.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 630,640 shares of the biopharmaceutical company's stock valued at $14,492,000 after acquiring an additional 3,652 shares during the last quarter. Arizona State Retirement System boosted its holdings in Xencor by 13.3% in the fourth quarter. Arizona State Retirement System now owns 18,190 shares of the biopharmaceutical company's stock valued at $418,000 after purchasing an additional 2,132 shares during the period. Raymond James Financial Inc. purchased a new position in Xencor in the fourth quarter valued at $2,329,000. PNC Financial Services Group Inc. lifted its holdings in Xencor by 49.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock worth $93,000 after buying an additional 1,337 shares during the last quarter. Finally, Amundi increased its position in shares of Xencor by 225.0% during the fourth quarter. Amundi now owns 35,380 shares of the biopharmaceutical company's stock worth $829,000 after purchasing an additional 24,494 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.